StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Vertex (VRTX) PT Raised to $229 at Cantor Fitzgerald
November 19, 2019 11:11 AM
Cantor Fitzgerald analyst Alethia Young ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst PT Change
Next Articles
CRISPR Therapeutics (CRSP), Vertex (VRTX) Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobino
November 19, 2019 7:02 AM
Guggenheim Upgrades Vertex (VRTX) to Buy
November 19, 2019 7:01 AM
CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies
November 19, 2019 7:00 AM
